

## Congestive Heart Failure

### REFERENCES

- Adlam D , Silcocks P , et al. Using BNP to develop a risk score for heart failure in primary care. *Eur Heart J* . 2005;26:1086-1093.
- Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. *J Am Geriatr Soc*. 2003;51:123-126.
- American Heart Association. Heart Disease and Stroke Statistics—2004 Update . Dallas , Tex : American Heart Association; 2004.
- Anker SD , Chua TP , et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. *Circulation*. 1997;96:526-534.
- Awata N, et al. The effects of coenzyme Q10 on ischemic heart disease evaluated by dynamic exercise test. In: Yamamura Y, Folkers K, et al, eds. *Biomedical and Clinical Aspects of Coenzyme Q*. Vol 2. Amsterdam , Netherlands : Elsevier-North Holland Biomedical; 1980:247-254.
- Benedict CR, Johnstone DE , et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. *J Am Coll Cardiol*. 1994;23:1410-1420.
- Berger MM , Mustafa I . Metabolic and nutritional support in acute cardiac failure. *Curr Opin Clin Nutr Metab Care*. 2003;6:195-201.
- Berman M, Erman A, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. *Clin Cardiol*. 2004;27:295-299.
- Braunwald E. Heart failure. In: Braunwald E, Fauci AS, et al, eds. *Harrison's Principles of Internal Medicine*. 15th ed. New York , NY : McGraw Hill Professional Publishing; 2001:1318-1328.
- Cohen N, Alon I, et al. Metabolic and clinical effects of oral magnesium supplementation in furosemide-treated patients with severe congestive heart failure. *Clin Cardiol*. 2000;23:433-436.
- Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. *Am Heart J*. 2000;139(pt 3):S124-S130.
- Crane FL , Navas P. The diversity of coenzyme Q function. *Mol Aspects Med*. 1997;18(suppl):S1-S6.
- Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. *Kidney Int*. 1987;31:1402-1415.
- Dzau VJ, Colucci WS, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. *Circulation*. 1981;63:645-651.
- Dzugan SA, Arnold Smith R. Hypercholesterolemia treatment: a new hypothesis or just an accident? *Med Hypotheses*. 2002;59:751-756.
- Eichholzer M, Stahelin HB, et al. Inverse correlation between essential antioxidants in plasma and subsequent risk to develop cancer, ischemic heart disease and stroke respectively: 12-year follow-up of the Prospective Basel Study. *EXS*. 1992;62:398-410.
- Fedak PW, Verma S, et al. Cardiac remodeling and failure: from molecules to man (part I). *Cardiovasc Pathol*. 2005;14:1-11.
- Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. *Prev Cardiol*. 2000;3:24-32.
- Frei B, Kim MC, et al. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. *Proc Natl Acad Sci*

Goa KL, Brogden RN. L-carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. *Drugs*. 1987;34:1-24.

Hunt SA, Baker DW, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *J Heart Lung Transplant*. 2002;21:189-203.

Jeejeebhoy F, Keith M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. *Am Heart J*. 2002;143:1092-1100.

Jessup M, Brozena S. Heart failure. *N Engl J Med*. 2003;348:2007-2018.

Judy WV, Folkers K, et al. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, et al, eds. *Biomedical and Clinical Aspects of Coenzyme Q*. Vol 4. Amsterdam , Netherlands : Elsevier Science;1991:291-298.

Kontoleon PE, Anastasiou-Nana MI, et al. Hormonal profile in patients with congestive heart failure. *Int J Cardiol*. 2003;87:179-183.

Kostis JB, Shelton BJ, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. *Am Heart J*. 1994;128:358-364.

Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure: a placebo controlled randomized double-blind study. *Fortschr Med*. 1993;111:352-354.

Mancini M, Rengo F, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. *A rzneimittelforschung*. 1992;42:1101-1104.

Maxwell SR. Can anti-oxidants prevent ischaemic heart disease? *J Clin Pharm Ther*. 1993;18:85-95.

McCullough PA, Philbin EF, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study . *J Am Coll Cardiol*. 2002;39:60-69 .

Moriyama Y, Yasue H, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. *J Clin Endocrinol Metab*. 2000;85:1834-1840.

Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure; rationale, design and end-points of "Q-symbio"—a multinational trial. *Biofactors*. 2003;18:79-89.

Nakamura Y, Takahashi M, et al. Protection of ischaemic myocardium with coenzyme Q10. *Cardiovasc Res*. 1982;16:132-137.

Nayler WG. The use of coenzyme Q10 to protect ischaemic heart muscle. In: Yamamura Y, Folkers K, et al, eds. *Biomedical and Clinical Aspects of Coenzyme Q*. Vol 2. Amsterdam , Netherlands : Elsevier-North Holland Biomedical; 1980:409-425.

Ondarroa M, Quinn PJ. Proton magnetic resonance spectroscopic studies of the interaction of ubiquinone-10 with phospholipid model membranes. *Eur J Biochem*. 1986;155:353-361.

Patrick L. Mercury toxicity and antioxidants, part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. *Alter Med Rev*. 2002;7:456-471.

Pucciarelli G, Mastursi M, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure . *Clin Ter*. 1992;141:379-384.

Pugh PJ, Jones RD , et al. Testosterone treatment for men with chronic heart failure. *Heart*. 2004;90:446-447.

Schaffer SW, Lombardini JB, et al. Interaction between the actions of taurine and angiotensin II. *Amino Acids*. 2000;18:305-318.

Schmidt U, et al. Efficacy of the hawthorn (*Crataegus*) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. *Phytomedicine*. 1994;1:17-24.

Schwinger RH, Pietsch M, et al. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. *J Cardiovasc Pharmacol.* 2000;35:700-707.

Steg PG , Joubin L , et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. *Chest.* 2005;128:21-29.

Taggart DP, Jenkins M, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. *Ann Thorac Surg.* 1996;61:829-833.

Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. *Am Heart J.* 2002;143:910-915.

Tauchert M, Gildor A, et al. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure . *Herz.* 1999;24:465-474.

Weant KA , Smith KM . The role of coenzyme Q10 in heart failure. *Ann Pharmacother.* 2005;39:1522-1526.

Weigl A, Assmus KD, et al. Crataegus Special Extract WS 1442: assessment of objective effectiveness in patients with heart failure (NYHA II). *Fortschr Med.* 1996;114:291-296.

Weisberg AD, Albornoz F, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotension II/salt-induced aortic remodeling. *Arterioscler Thromb Vasc Biol.* 2005;25:365-371.

Witte KK , Clark AL . Fish oils—adjuvant therapy in chronic heart failure? *Eur J Cardiovasc Prev Rehabil.* 2004;11:267-274.

Witte KK , Nikitin NP , et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. *Eur Heart J.* 2005

Zile MR , Brutsaert DL . New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, and measurements of diastolic function. *Circulation.* 2002;105:1387-1393.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

**LifeExtension®**

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.